Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: Implications for pharmacogene therapy

Cancer Gene Therapy

Volumn 9, Issue 2, 2002, Pages 178-188

  Frank, Susanne ^a   Steffens, Sabine ^a   Fischer, Ute ^a   Tlolko, Aurelia ^a   Rainov, Nikolai G ^b   Kramm, Christof M ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

2 aminoanthracene; 4 ipomeanol; Bystander effect; Cytochrome P450; Gene therapy

Indexed keywords

2 AMINOANTHRACENE; 4 IPOMEANOL; CYTOCHROME P450; CYTOCHROME P450 4B1; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; PRODRUG; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ALLOGENEIC RESTRICTION; ANIMAL CELL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL ACTIVATION; CELL CYCLE; CELL CYCLE S PHASE; CELL DAMAGE; CELL KILLING; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; GENE THERAPY; GENE TRANSFER; GLIOSARCOMA; HERPES SIMPLEX VIRUS 1; LYMPHOCYTE; MARKER GENE; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTHRACENES; ANTIVIRAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; BLOTTING, WESTERN; BYSTANDER EFFECT; CELL CYCLE; CELL SURVIVAL; CYTOCHROME P-450 ENZYME SYSTEM; FLOW CYTOMETRY; GANCICLOVIR; GENE THERAPY; GLIOSARCOMA; GREEN FLUORESCENT PROTEINS; HERPESVIRUS 1, HUMAN; HUMANS; LUMINESCENT PROTEINS; PHARMACOGENETICS; PRODRUGS; RABBITS; TERPENES; THYMIDINE KINASE; TRANSFECTION; TUMOR CELLS, CULTURED;

ANIMALIA; HUMAN HERPESVIRUS 1; ORYCTOLAGUS CUNICULUS; SIMPLEXVIRUS;

EID: 85047698115     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700422     Document Type: Article

References (33)

1. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
2. Gene therapy for brain tumors
3. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
4. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
5. An experimental model of retrovirus gene therapy for malignant brain tumors
6. The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified
7. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors
8. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol
9. A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug-activating gene delivery and for gene therapy in malignant glioma
10. Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: Applications for prodrug-activating gene therapy
11. Metabolic activation of 4-ipomeanol by complementary DNA-expressed human cytochromes P-450: Evidence for species- specific metabolism
12. CYP4B1 activates 4-ipomeanol in rat lung
13. 4-Ipomeanol and 2-aminoanthracene cytotoxicity in C3H/10T1/2 cells expressing rabbit cytochrome P450 4B1
14. The 9L rat brain tumor: Description and application of an animal model
15. Tumor cell endocytosis imaging facilitates delineation of the glioma-brain interface
16. The biochemistry and mechanism of action of acyclovir
17. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human alpha and human beta polymerases. A unique inhibition mechanism for 9 -(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate
18. "Bystander killing" induces apoptosis and is inhibited by forskolin
19. The bystander effect in gene therapy: Great, but how does it work?
20. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes
21. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene
22. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy
23. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide
24. Diffusable cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm
25. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation
26. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
27. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: Clinical follow-up and improved new vectors
28. Use of donor T-lymphocytes expressing herpes simplex thymidine kinase in allogeneic bone marrow transplantation: A phase I-II study
29. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
30. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions
31. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: Where we now stand
32. Herpes simplex thymidine kinase (HStk) transgenic donor lymphocytes
33. Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: An approach for specific in vivo donor T-cell depletion after bone marrow transplantation?